Judith Ochs

5.3k total citations · 3 hit papers
14 papers, 4.3k citations indexed

About

Judith Ochs is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Judith Ochs has authored 14 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Judith Ochs's work include Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Judith Ochs is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Judith Ochs collaborates with scholars based in United States, Singapore and Germany. Judith Ochs's co-authors include Roy S. Herbst, Steven D. Averbuch, David H. Johnson, Giuseppe Giaccone, Christian Manegold, Michael Wolf, Ronald B. Natale, Joan H. Schiller, Vincent A. Miller and Abderrahim Fandi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer.

In The Last Decade

Judith Ochs

14 papers receiving 4.2k citations

Hit Papers

Gefitinib in Combination With Gemcitabine and Cisplatin i... 2004 2026 2011 2018 2004 2004 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
    2004 1.4k citations Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology profile →
  2. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →
  3. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    2005 518 citations Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judith Ochs United States 11 3.3k 3.3k 1.1k 597 265 14 4.3k
Russell F. DeVore United States 17 2.4k 0.7× 2.8k 0.8× 1.3k 1.2× 460 0.8× 105 0.4× 29 3.8k
Abderrahim Fandi United States 20 3.0k 0.9× 3.2k 1.0× 1.1k 1.0× 552 0.9× 113 0.4× 50 4.4k
Radj Gervais France 24 4.0k 1.2× 3.7k 1.1× 1.1k 1.0× 617 1.0× 137 0.5× 83 5.2k
Shinzoh Kudoh Japan 27 4.5k 1.4× 4.0k 1.2× 1.3k 1.1× 489 0.8× 111 0.4× 84 5.7k
Sang-We Kim South Korea 22 4.1k 1.3× 3.8k 1.2× 1.6k 1.5× 834 1.4× 207 0.8× 47 5.2k
Martin Sebastian Germany 27 3.3k 1.0× 4.1k 1.3× 1.7k 1.6× 930 1.6× 162 0.6× 117 5.8k
Shunichi Sugawara Japan 36 3.5k 1.1× 4.2k 1.3× 1.1k 1.0× 548 0.9× 112 0.4× 209 5.4k
Richard Eek Australia 9 2.0k 0.6× 2.1k 0.6× 652 0.6× 326 0.5× 139 0.5× 39 2.7k
Panos Fidias United States 25 1.8k 0.6× 1.7k 0.5× 925 0.8× 276 0.5× 116 0.4× 58 3.0k
Sang‐We Kim South Korea 36 3.9k 1.2× 3.5k 1.1× 1.4k 1.3× 743 1.2× 306 1.2× 207 5.4k

Countries citing papers authored by Judith Ochs

Since Specialization
Citations

This map shows the geographic impact of Judith Ochs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Ochs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Ochs more than expected).

Fields of papers citing papers by Judith Ochs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Ochs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Ochs. The network helps show where Judith Ochs may publish in the future.

Co-authorship network of co-authors of Judith Ochs

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Ochs. A scholar is included among the top collaborators of Judith Ochs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Ochs. Judith Ochs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Giaccone, Giuseppe, Renee Iacona, Abderrahim Fandi, et al.. (2008). Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. Journal of Cancer Research and Clinical Oncology. 135(3). 467–476. 9 indexed citations
2.
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, et al.. (2006). Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma. Clinical Cancer Research. 12(3). 860–868. 155 indexed citations
3.
Bell, Daphne W., Thomas J. Lynch, Sara M. Haserlat, et al.. (2005). Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology. 23(31). 8081–8092. 518 indexed citations breakdown →
4.
Cella, David, Roy S. Herbst, Thomas J. Lynch, et al.. (2005). Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. Journal of Clinical Oncology. 23(13). 2946–2954. 104 indexed citations
5.
Ochs, Judith. (2004). Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. International Journal of Radiation Oncology*Biology*Physics. 58(3). 941–949. 44 indexed citations
6.
Giaccone, Giuseppe, Roy S. Herbst, Christian Manegold, et al.. (2004). Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. Journal of Clinical Oncology. 22(5). 777–784. 1388 indexed citations breakdown →
7.
Herbst, Roy S., Giuseppe Giaccone, Joan H. Schiller, et al.. (2004). Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal of Clinical Oncology. 22(5). 785–794. 1374 indexed citations breakdown →
8.
Miller, Vincent A., David H. Johnson, Lee M. Krug, et al.. (2003). Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 21(11). 2094–2100. 56 indexed citations
9.
Herbst, Roy S., Anne‐Marie Maddox, Mace L. Rothenberg, et al.. (2002). Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial. Journal of Clinical Oncology. 20(18). 3815–3825. 496 indexed citations
10.
Walter, Andrew W., Amar Gajjar, Judith Ochs, et al.. (1998). Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study. Medical and Pediatric Oncology. 30(1). 28–33. 46 indexed citations
11.
12.
Mulhern, Raymond K., Marc E. Horowitz, Judith Ochs, et al.. (1989). Assessment of quality of life among pediatric patients with cancer.. Psychological Assessment. 1(2). 130–138. 59 indexed citations
13.
Pui, Ching-Hon, W. Paul Bowman, Minnie Abromowitch, et al.. (1985). ELECTIVE TESTICULAR BIOPSY DURING CHEMOTHERAPY FOR CHILDHOOD LEUKAEMIA IS OF NO CLINICAL VALUE. The Lancet. 326(8452). 410–412. 50 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Russell F. DeVore Breakdown of academic impact, for papers by Abderrahim Fandi Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by Shinzoh Kudoh Breakdown of academic impact, for papers by Sang-We Kim Breakdown of academic impact, for papers by Martin Sebastian Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Richard Eek Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Sang‐We Kim
Rankless by CCL
2026